Ubs Asset Management Americas Inc Madrigal Pharmaceuticals, Inc. Transaction History
Ubs Asset Management Americas Inc
- $379 Billion
- Q1 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 26,363 shares of MDGL stock, worth $7.87 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
26,363
Previous 27,538
4.27%
Holding current value
$7.87 Million
Previous $8.5 Million
2.77%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding MDGL
# of Institutions
367Shares Held
23.2MCall Options Held
979KPut Options Held
459K-
Janus Henderson Group PLC London, X02.21MShares$658 Million0.42% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.1MShares$626 Million39.89% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.02MShares$603 Million10.84% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$595 Million10.82% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$589 Million7.8% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.1B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...